|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| CURRENT ASSETS: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Accounts receivable, net of credit losses of December 31, 2024 $14,281 ($0 as of December 31, 2023) | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total accounts receivable, net of credit losses of December 31, 2024 $14,281 ($0 as of December 31, 2023) | ||||||||||||||||||||
| Prepaid expenses and other receivables | ||||||||||||||||||||
| Receivables from related parties | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total receivables from related parties | ||||||||||||||||||||
| Convertible loan to related party | ||||||||||||||||||||
| Loans receivable | ||||||||||||||||||||
| Convertible loan | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| NON CURRENT ASSETS: | ||||||||||||||||||||
| Deposits | ||||||||||||||||||||
| Investments and loans to associates | ||||||||||||||||||||
| Investments to associates | ||||||||||||||||||||
| Equity investees | ||||||||||||||||||||
| Loans to associates | ||||||||||||||||||||
| Property, plants and equipment, net | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Deferred tax | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total non-current assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| Liabilities and equity | ||||||||||||||||||||
| CURRENT LIABILITIES: | ||||||||||||||||||||
| Short-term bank credit | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Total accounts payable | ||||||||||||||||||||
| Advance payments from Germfree (See note 11a) | ||||||||||||||||||||
| Accrued expenses and other payables | ||||||||||||||||||||
| Income tax payable | ||||||||||||||||||||
| Employees and related payables | ||||||||||||||||||||
| Other payable related parties | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total other payable related parties | ||||||||||||||||||||
| Advance payments on account of grant | ||||||||||||||||||||
| Contract liabilities | ||||||||||||||||||||
| Short-term loans | ||||||||||||||||||||
| Current maturities of finance leases | ||||||||||||||||||||
| Current maturities of operating leases | ||||||||||||||||||||
| Current maturities of convertible loans | ||||||||||||||||||||
| Short-term and current maturities of convertible loans | ||||||||||||||||||||
| TOTAL CURRENT LIABILITIES | ||||||||||||||||||||
| LONG-TERM LIABILITIES: | ||||||||||||||||||||
| Non-current operating leases | ||||||||||||||||||||
| Loans payable | ||||||||||||||||||||
| Convertible loans | ||||||||||||||||||||
| Retirement benefits obligation | ||||||||||||||||||||
| Finance Lease, Long-term leases obligations | ||||||||||||||||||||
| Advance payments on account of grant | ||||||||||||||||||||
| Contingent liability (see note 4) | ||||||||||||||||||||
| Contingent consideration (see note 4) | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| TOTAL LONG-TERM LIABILITIES | ||||||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||||||
| REDEEMABLE NON-CONTROLLING INTEREST | ||||||||||||||||||||
| EQUITY (CAPITAL DEFICIENCY): | ||||||||||||||||||||
| Common stock of $0.0001 par value Authorized at December 31, 2024 and December 31, 2023: 14,583,333 shares; Issued at December 31, 2024 and December 31, 2023: 5,199,963 and 3,216,363 shares, respectively; Outstanding at December 31, 2024 and December 31, 2023: 5,171,306 and 3,187,706 shares, respectively. | ||||||||||||||||||||
| Receipts on account of shares to be allotted | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Receipts on account of shares and warrants to be allotted | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Treasury stock 286,567 shares as of December 31, 2024 and December 31, 2023 | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Equity attributable to Orgenesis Inc. | ||||||||||||||||||||
| Non-controlling interests | ||||||||||||||||||||
| TOTAL EQUITY (CAPITAL DEFICIENCY) | ||||||||||||||||||||
| TOTAL LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST AND EQUITY (CAPITAL DEFICIENCY) | ||||||||||||||||||||
Loading...
